- Thanks to the relaxed social restrictions, Texas Roadhouse has reversed the months-long decline in comparable sales.
- The pandemic’s resurgence is threatening the nascent recovery and outstanding share performance.
- Yet, with a solid balance sheet and strategies to suit the new normal, the company can withstand a prolonged slowdown as vaccine hopes set to revive the industry.
- Despite a sharp premium in the valuation multiple, Texas Roadhouse is a ‘Buy’ as we expect the vaccine-driven momentum to outsmart the valuation fundamentals.
For further details see:
Texas Roadhouse: The Pandemic Shapes An All-Weather Stock